Table 2 Economic evaluation of the main COVID-19 clinical pathways
From: COVID-19 and hospital management costs: the Italian experience
Clinical Pathway | Complexity Area of Access | Length of stay in the area of Access (# days) | Internal Ward transfer | Length of stay in the Internal Ward transfer (# days) | Economic evaluation of the clinical pathway (€) | Total Length of stay (# days) |
|---|---|---|---|---|---|---|
Clinical Pathway #1 (5.38% of patients) | Low-complexity hospitalization | 8.8 | High-complexity hospitalization | 9.6 | 17,629.63€ | 18.4 |
Clinical Pathway #2 (15.84% of patients) | Low-complexity hospitalization | 6.5 | Medium-complexity hospitalization | 11.2 | 10,941.41€ | 17.7 |
Clinical Pathway #3 (8.34% of patients) | Medium-complexity hospitalization | 9.1 | High-complexity hospitalization | 14.2 | 26,339.20€ | 23.4 |
Clinical Pathway #4 (29.06% of patients) | Medium-complexity hospitalization | 8.6 | Low-complexity hospitalization | 10.0 | 10,778.04€ | 18.6 |
Clinical Pathway #5 (11.67% of patients) | High-complexity hospitalization | 10.0 | Medium-complexity hospitalization | 12.6 | 22,857.28€ | 22.6 |
Pathway #6 (9.01% of patients) | Low-complexity hospitalization | 6,198.02€ | 13.0 | |||
Pathway #7 (16.91% of patients) | Medium-complexity hospitalization | 7,152.53€ | 10.2 | |||
Pathway #8 (3.79% of patients) | High-complexity hospitalization | 15,544.32€ | 11.0 | |||